Berns, Chief and President Executive Officer of Allos. We ended the third quarter without debt and $100.4 million in cash and investments, which based on our historical sales levels for the first nine months of 2011, we believe will be enough to fund our operations through early 2014. Achievement of growth in U.S. Sales and/or potential milestone obligations and royalties associated with regulatory authorization of FOLOTYN in the EU would additional extend our cash assets. .. Allos terminates AMAG merger contract with AMAG Allos Therapeutics, Inc. announced today that the Contract and Strategy of Merger and Reorganization entered into by and among Allos, Alamo and AMAG Acquisition Sub, Inc.Lung transplant individuals are among the most vulnerable because they have weakened immune systems due to the immunosuppressive drugs they have to try prevent organ rejection, research writer Dr. David Ruttens stated in a European Lung Base news launch. Ruttens is a specialist in respiratory medicine at the University of Leuven in Belgium. During the 6 years of follow-up nearly, about 45 % of the patients passed away and 47 % experienced organ rejection.